Clinical Trial: GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma

U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07768943) titled 'GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma' on Aug. 12.

Brief Summary: This prospective, multicenter study evaluates a response-adapted treatment strategy for previously untreated patients with early-stage extranodal NK/T-cell lymphoma of the upper aerodigestive tract.

All participants receive two cycles of GELAD induction chemotherapy, followed by early response assessment using positron emission tomography/computed tomography (PET/CT) and plasma Epstein-Barr virus (EBV) DNA. Subsequent treatment is determined by the early response.

Participants with complete metabolic response and negati...